Does seropositivity influence differentially drug discontinuation of biologic antirheumatic agents with non-anti-tnf mode of action?

A Finckh; D Courvoisier; J-E Gottenberg; X Mariette; J Morel; SA Bergstra; V Hernandez; C Codreanu; TK Kvien; MJ Santos; K Pavelka; M Hetland; K Chatzidionysiou; J Askling; C Turesson; C Gabay; R Van Vollenhoven

doi:10.1136/annrheumdis-2017-eular.6006

Does seropositivity influence differentially drug discontinuation of biologic antirheumatic agents with non-anti-tnf mode of action?

A Finckh, D Courvoisier, J-E Gottenberg, X Mariette, J Morel, SA Bergstra, V Hernandez, C Codreanu, TK Kvien, MJ Santos, K Pavelka, M Hetland, K Chatzidionysiou, J Askling, C Turesson, C Gabay, R Van Vollenhoven

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Originalsprog	Engelsk
Artikelnummer	FRI0221
Tidsskrift	Annals of the Rheumatic Diseases
Vol/bind	76
Udgave nummer	Suppl 2
Sider (fra-til)	567
ISSN	0003-4967
DOI	https://doi.org/10.1136/annrheumdis-2017-eular.6006
Status	Udgivet - 2017

Adgang til dokumentet

10.1136/annrheumdis-2017-eular.6006

Biblioteksadgang?

Tjek tilgængelighed hos det Kgl. Bibliotek

Citationsformater

Finckh, A., Courvoisier, D., Gottenberg, J.-E., Mariette, X., Morel, J., Bergstra, SA., Hernandez, V., Codreanu, C., Kvien, TK., Santos, MJ., Pavelka, K., Hetland, M., Chatzidionysiou, K., Askling, J., Turesson, C., Gabay, C., & Vollenhoven, R. V. (2017). Does seropositivity influence differentially drug discontinuation of biologic antirheumatic agents with non-anti-tnf mode of action? Annals of the Rheumatic Diseases, 76(Suppl 2), 567. Artikel FRI0221. https://doi.org/10.1136/annrheumdis-2017-eular.6006

Finckh, A, Courvoisier, D, Gottenberg, J-E, Mariette, X, Morel, J, Bergstra, SA, Hernandez, V, Codreanu, C, Kvien, TK, Santos, MJ, Pavelka, K, Hetland, M, Chatzidionysiou, K, Askling, J, Turesson, C, Gabay, C & Vollenhoven, RV 2017, 'Does seropositivity influence differentially drug discontinuation of biologic antirheumatic agents with non-anti-tnf mode of action?', Annals of the Rheumatic Diseases, bind 76, nr. Suppl 2, FRI0221, s. 567. https://doi.org/10.1136/annrheumdis-2017-eular.6006

@article{2d65c8ee72de4a37b1c05765453fd27f,

title = "Does seropositivity influence differentially drug discontinuation of biologic antirheumatic agents with non-anti-tnf mode of action?",

author = "A Finckh and D Courvoisier and J-E Gottenberg and X Mariette and J Morel and SA Bergstra and V Hernandez and C Codreanu and TK Kvien and MJ Santos and K Pavelka and M Hetland and K Chatzidionysiou and J Askling and C Turesson and C Gabay and Vollenhoven, {R Van}",

year = "2017",

doi = "10.1136/annrheumdis-2017-eular.6006",

language = "English",

volume = "76",

pages = "567",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",